195 related articles for article (PubMed ID: 27787556)
1. Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia.
Jurcic JG
JAMA Oncol; 2017 Mar; 3(3):299-300. PubMed ID: 27787556
[No Abstract] [Full Text] [Related]
2. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
Maiti A; DiNardo CD; Daver NG; Rausch CR; Ravandi F; Kadia TM; Pemmaraju N; Borthakur G; Bose P; Issa GC; Short NJ; Yilmaz M; Montalban-Bravo G; Ferrajoli A; Jabbour EJ; Jain N; Ohanian M; Takahashi K; Thompson PA; Loghavi S; Montalbano KS; Pierce S; Wierda WG; Kantarjian HM; Konopleva MY
Blood Cancer J; 2021 Feb; 11(2):25. PubMed ID: 33563904
[No Abstract] [Full Text] [Related]
3. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
4. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
Carter BZ; Tao W; Mak PY; Ostermann LB; Mak D; McGeehan G; Ordentlich P; Andreeff M
Blood; 2021 Oct; 138(17):1637-1641. PubMed ID: 34232981
[No Abstract] [Full Text] [Related]
5. Molecularly targeted therapies for acute myeloid leukemia.
Stein EM
Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775
[TBL] [Abstract][Full Text] [Related]
6. [European approvals: Glasdegib for Acute myeloid leukemia].
Barrière S; Gastaud L
Bull Cancer; 2020 Dec; 107(12):1206-1207. PubMed ID: 33070952
[No Abstract] [Full Text] [Related]
7. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
Aldoss I; Marcucci G
Chin Clin Oncol; 2019 Oct; 8(S1):S25. PubMed ID: 31684734
[No Abstract] [Full Text] [Related]
8. ＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Naoe T
Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
[TBL] [Abstract][Full Text] [Related]
9. [The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
Ai H; Mi RH; Chen L; Ji X; Yin QS; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):956-959. PubMed ID: 36709189
[No Abstract] [Full Text] [Related]
10. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara F
Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
[No Abstract] [Full Text] [Related]
11. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
[No Abstract] [Full Text] [Related]
12. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
13. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
14. [Advances in the genetic abnormalities involved in the pathogenesis of acute myeloid leukemia].
Arbelbide JA
Rev Fac Cien Med Univ Nac Cordoba; 2019 Jun; 76(2):77-78. PubMed ID: 31216160
[No Abstract] [Full Text] [Related]
15. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
16. How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD; Wei AH
Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia drug development in the post-venetoclax era.
Pollyea DA
Am J Hematol; 2019 Sep; 94(9):959-962. PubMed ID: 31179583
[No Abstract] [Full Text] [Related]
18. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.
Niscola P; Noguera NI; Catalano G; Cupelli L; Fratoni S; Giovannini M; Mazzone C; Neri B; Scaramucci L; Trawinska MM; de Fabritiis P; Abruzzese E
Acta Oncol; 2019 Jun; 58(6):888-890. PubMed ID: 30848978
[No Abstract] [Full Text] [Related]
19. Targeting MCL1, Companies Aim to Unblock Apoptosis.
Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
[TBL] [Abstract][Full Text] [Related]
20. Prospects for Venetoclax in Myelodysplastic Syndromes.
Garcia JS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
